VOLITIONRX LIMITED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.805 USD | +11.81% |
|
-7.61% | +11.59% |
| Apr. 26 | VolitionRx Limited Announces Board Changes | CI |
| Apr. 23 | VolitionRx Limited Launches In-Clinic in U.S. and Europe Through Antech | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 3.63M | Sales 2025 * | 16.48M | Capitalization | 59.12M |
|---|---|---|---|---|---|
| Net income 2024 * | -36M | Net income 2025 * | -32M | EV / Sales 2024 * | 13.8 x |
| Net cash position 2024 * | 8.9M | Net Debt 2025 * | 18.4M | EV / Sales 2025 * | 4.7 x |
| P/E ratio 2024 * |
-1.77
x | P/E ratio 2025 * |
-2.23
x | Employees | 110 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on VolitionRx Limited
More recommendations
More press releases
| 1 day | +11.81% | ||
| 1 week | -7.61% | ||
| Current month | -11.09% | ||
| 1 month | +9.62% | ||
| 3 months | -32.19% | ||
| 6 months | -6.97% | ||
| Current year | +11.59% |
1 week
0.72
0.91
1 month
0.571.02
Current year
0.571.23
1 year
0.552.05
3 years
0.554.14
5 years
0.556.84
10 years
0.559.28
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 11-10-05 |
Terig Hughes
DFI | Director of Finance/CFO | 54 | 21-01-31 |
Gaetan Michel
COO | Chief Operating Officer | 51 | 21-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cameron Reynolds
CEO | Chief Executive Officer | 53 | 11-10-05 |
Martin Faulkes
CHM | Chairman | 80 | 11-10-05 |
Guy Innes
BRD | Director/Board Member | 67 | 11-10-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-08 | 0.8 | +11.12% | 75 287 |
| 24-05-07 | 0.72 | -7.61% | 304,804 |
| 24-05-06 | 0.7793 | -12.53% | 182,092 |
| 24-05-03 | 0.8909 | +1.43% | 108,909 |
| 24-05-02 | 0.8783 | +1.42% | 79,071 |
Delayed Quote Nyse, May 08, 2024 at 12:45 pm EDT
More quotes
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.72
USD
Average target price
3.725
USD
Spread / Average Target
+417.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.59% | 59.12M | |
| -17.94% | 11.29B | |
| +64.64% | 3.91B | |
| -30.74% | 2.29B | |
| -10.77% | 2.23B | |
| -27.01% | 1.61B | |
| +33.28% | 1.19B | |
| -2.40% | 752M | |
| -34.08% | 458M | |
| +14.91% | 338M |
- Stock Market
- Equities
- VNRX Stock